Boardroom Alpha
Boardroom Alpha
ZYME · Current Report (Form 8-K) · Filed December 30, 2025

Zymeworks Inc — Current Report (Form 8-K)

Form
8-K
Filed
December 30, 2025
Period
Dec 30, 2025
Ticker
ZYME
Accession
0001193125-25-337268
Boardroom Alpha · Filing insights

Stockholders elected directors, approved executive compensation, and ratified KPMG LLP as auditor at the 2025 annual meeting.

About Zymeworks Inc
Market cap
$1.8B
1Y TSR
+102.4%
3Y TSR
+43.8%
Board grade
B-
Sector
Healthcare
CEO
Kenneth Galbraith
Last annual meeting: Dec 30, 2025 · View full Zymeworks Inc profile →
8-K
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 30, 2025

 

 

Zymeworks Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-41535   88-3099146
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

108 Patriot Drive, Suite A

Middletown, Delaware

  19709
(Address of principal executive offices)   (Zip Code)

(302) 274-8744

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, par value $0.00001 per share   ZYME   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


Item 5.07

Submission of Matters to a Vote of Security Holders.

On Tuesday, December 30, 2025, Zymeworks Inc. (the “Company”), held its 2025 annual meeting of stockholders (the “Annual Meeting”) at 9:00 a.m. Pacific Time, virtually via live audio webcast. As of the close of business on November 3, 2025, the record date for the Annual Meeting, there were 74,835,565 shares of common stock entitled to vote at the meeting and 553,184 exchangeable shares of Zymeworks ExchangeCo Ltd., a company existing under the laws of the Province of British Columbia and an indirect subsidiary of the Company (“ExchangeCo”), entitled to exercise voting rights at the meeting. 63,222,722 shares of common stock and 400 exchangeable shares were present in person or by proxy at the Annual Meeting, representing approximately 84.48% of the Company’s common stock and 0.07% of ExchangeCo’s exchangeable shares entitled to vote at the Annual Meeting, and together representing 83.86% of the voting power of the capital stock of the Company, which constituted a quorum for the transaction of business.

Set forth below are the matters acted upon by the Company’s stockholders and holders of exchangeable shares (collectively, the “securityholders”) at the Annual Meeting, and the final voting results on each matter. Each of the proposals are described in further detail in the Company’s definitive proxy statement dated November 10, 2025, filed with the Securities and Exchange Commission on November 10, 2025.

Proposal 1 – Election of Directors

 

  1.

The following nominees were elected as directors to serve until their term expires or until their successors are duly elected or appointed.

 

Nominee

   Votes For      % Votes For     Votes Withheld      % Votes
Withheld
    Broker
Non-Votes
 

Carlos Campoy

     53,922,255        94.35     3,231,897        5.65     6,068,970  

Alessandra Cesano

     45,985,104        80.46     11,169,048        19.54     6,068,970  

Robert E. Landry

     55,404,212        96.94     1,749,940        3.06     6,068,970  

Proposal 2 – Advisory Vote on the Compensation of Named Executive Officers

 

  2.

The securityholders approved, on an advisory and non-binding basis, the compensation of the Company’s named executive officers. There were 6,068,970 broker non-votes for this proposal.

 

Votes For

  

% Votes For

  

Votes Against

  

% Votes Against

  

Votes Abstaining

  

% Votes
Abstaining

53,710,820    93.98%    3,391,788    5.93%    51,544    0.09%

Proposal 3 – Ratification of Appointment of Auditor

 

  3.

The securityholders ratified the appointment of KPMG LLP, chartered professional accountants, as the Company’s auditors for the year ending December 31, 2025. There were 0 broker non-votes for this proposal.

 

Votes For

  

% Votes For

  

Votes Against

  

% Votes Against

  

Votes Abstaining

  

% Votes
Abstaining

62,934,142    99.54%    263,022    0.42%    25,958    0.04%

 

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

        ZYMEWORKS INC.
    (Registrant)
Date: December 30, 2025     By:  

/s/ Kenneth Galbraith

   

Name:

Title:

 

Kenneth Galbraith

Chair of the Board of Directors, President and Chief Executive Officer

 

3

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Zymeworks Inc (ZYME)

Reference

Frequently asked questions

When did Zymeworks Inc file this 8-K?
Zymeworks Inc (ZYME) filed this Current Report (Form 8-K) with the SEC on December 30, 2025. The accession number assigned by EDGAR is 0001193125-25-337268.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders elected directors, approved executive compensation, and ratified KPMG LLP as auditor at the 2025 annual meeting. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Zymeworks Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Zymeworks Inc has filed under CIK 1937653, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer